
    
      Study population:

      Patients with advanced non-small-cell lung cancer who have not received treatment for the
      disease at this stage and who have a good performance status (ECOG 0-1) and measurable
      disease (at least one target lesion according to RECIST criteria).

      Duration of treatment:

      Six chemotherapy cycles will be given. The duration of every cycle will be 21 days. If the
      treatment is beneficial, it may be prolonged to a total of 8 cycles at the discretion of the
      investigator.

      Calendar and planned finalization date:

      The approximate duration of the study is 3 years of recruitment followed by 1 year of
      follow-up.
    
  